1269755-11-4 Usage
General Description
(3R,4S)-rel-1-[(benzyloxy)carbonyl]-4-fluoropyrrolidine-3-carboxylic acid is a chemical compound with a complex structure. It is a pyrrolidine derivative with a carboxylic acid functional group and a fluorine atom attached to the pyrrolidine ring. The compound also contains a benzyloxy carbonyl group, which is a protecting group commonly used in organic synthesis. This chemical may have potential applications in medicinal chemistry or as a building block for the synthesis of more complex molecules. The specific stereochemistry and arrangement of functional groups make this compound a unique and potentially valuable tool for researchers in the fields of chemistry and pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 1269755-11-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,9,7,5 and 5 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1269755-11:
(9*1)+(8*2)+(7*6)+(6*9)+(5*7)+(4*5)+(3*5)+(2*1)+(1*1)=194
194 % 10 = 4
So 1269755-11-4 is a valid CAS Registry Number.
1269755-11-4Relevant articles and documents
N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES
-
, (2012/08/08)
The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.
PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
-
, (2011/04/14)
The present invention provides a compound of Formula (I) and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor.
